Grandville, United States
HemaClear by OHK Medical Devices, Inc. offers a revolutionary solution in the form of a tourniquet that ensures a bloodless and sterile surgical field. With more than 500,000 procedures conducted, it has gained traction as a standard of care in many leading hospitals worldwide, including The Hospital for Special Surgery in New York, Sinai Hospital of Baltimore, and the Shriners Hospitals for Children.
The tourniquet's unique features include exsanguination of over 95% of blood, providing a wider surgical field, sterile single-use design, quick application, and cost-effectiveness. These qualities make it an attractive option for orthopedic procedures, offering numerous benefits for both patients and medical professionals.
Founded in 2002, this biotechnology and medical devices company has made significant strides in the healthcare industry. Despite the absence of specific headquarters or recent investment details, HemaClear by OHK Medical Devices has proven its potential to disrupt the conventional practices in surgical procedures, making it an intriguing prospect for potential investors.
